Scientific Sessions 2025  /  Transformative Advances in Genome Engineering for Precision Therapy  /  Developing single course in vivo gene editing therapies for hyperlipidemia
Logo

American Heart Association

  45
  0

Final ID:

Developing single course in vivo gene editing therapies for hyperlipidemia

  • Kathiresan, Sekar  ( Verve Therapeutics , Boston , Massachusetts , United States )
  • Musunuru, Kiran  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Ishikawa, Kiyotake  ( ICAHN SCHOOL OF MEDICINE MOUNT SINA , New York , New York , United States )
    • Author Disclosures:
    Sekar Kathiresan: DO have relevant financial relationships ; Executive Role:Verve Therapeutics:Active (exists now) | Kiran Musunuru: DO have relevant financial relationships ; Individual Stocks/Stock Options:Verve Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Beam Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Nava Therapeutics:Active (exists now) ; Advisor:Capstan Therapeutics:Active (exists now) ; Advisor:LEXEO Therapeutics:Active (exists now) ; Ownership Interest:Variant Bio:Active (exists now) ; Advisor:Verve Therapeutics:Active (exists now) | Kiyotake Ishikawa: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Transformative Advances in Genome Engineering for Precision Therapy

Saturday, 11/08/2025 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
Development and evolution of novel genome engineering technologies

Newby Gregory, Gaudelli Nicole, Liu David

Treating cardiovascular disease with Base and Prime Editing

Seidman Christine, Steinmetz Lars, Olson Eric

More abstracts from these authors:
Gene Therapy and the Potential LDL-Cholesterol "Cure"

Parikh Victoria, Knowles Josh, Khera Amit, Kathiresan Sekar

Design of Heart-2: a phase 1b clinical trial of VERVE-102, an in vivo base editing medicine delivered by a GalNAc-LNP and targeting PCSK9 to durably lower LDL cholesterol

Vafai Scott, Fiedorek Fred, Karsten Verena, Jensen Chelsey, Falzone Richard, Lister Troy, Stolz Leslie, Khera Amit, Kathiresan Sekar, Bellinger Andrew

You have to be authorized to contact abstract author. Please, Login
Not Available